Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2021

Open Access 01-12-2021 | Prostate Cancer | Review Article

Global experience with PSMA-based alpha therapy in prostate cancer

Authors: Mike M. Sathekge, Frank Bruchertseifer, Mariza Vorster, Alfred Morgenstern, Ismaheel O. Lawal

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2021

Login to get access

Abstract

Purpose

This review discusses the current state of prostate-specific membrane antigen (PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC). With this in-depth discussion on the growing field of PSMA-based alpha therapy (PAT), we aimed to increase the interactions between basic scientists and physician–scientists in order to advance the field.

Methods

To achieve this, we discuss the potential, current status, and opportunities for alpha therapy and strategies, attempted to date, and important questions that need to be addressed. The paper reviews important concepts, including whom to treat, how to treat, what to expect regarding treatment outcome, and toxicity, and areas requiring further investigations.

Results

There is much excitement about the potential of this field. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other conventional therapies.

Conclusion

A better understanding of the strengths and limitations of PAT may help in creating an effective therapy for mCRPC and design a rational combinatorial approach to treatment by targeting different tumor pathways.
Literature
1.
2.
Gillessen S, Omlin A, Attard G. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC). Ann Oncol. 2015;26:1589–604.PubMedPubMedCentralCrossRef
3.
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–48.PubMedPubMedCentralCrossRef
4.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu KN, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.PubMedPubMedCentralCrossRef
5.
Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275–85.PubMedCrossRef
6.
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113–22.PubMedCrossRef
7.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.PubMedCrossRef
8.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.PubMedCrossRef
9.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809–18.PubMed
10.
O’Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59:1007–13.
11.
Benesová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.PubMedCrossRef
12.
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022–8.PubMedCrossRef
13.
14.
DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003;361:955–64.PubMedCrossRef
15.
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28.PubMedCrossRef
16.
Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555–63.PubMed
17.
Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane antigen-based therapeutics. Adv Urol. 2012;2012:973820.PubMedCrossRef
18.
Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552–8.PubMedCrossRef
19.
Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9–15.PubMedCrossRef
20.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of a-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.PubMedCrossRef
21.
Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, et al. Alpha particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS ONE. 2013;8:e64730.PubMedPubMedCentralCrossRef
22.
Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, et al. Cancer Res. 2007;67:1950–8.PubMedCrossRef
23.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19.PubMedPubMedCentralCrossRef
24.
Seidl C. Radioimmunotherapy with alpha-particle-emitting radionuclides. Immunotherapy. 2014;6:431–58.PubMedCrossRef
25.
Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH. Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer. Cancers (Basel). 2021;13:779.CrossRef
26.
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200–8.PubMedPubMedCentralCrossRef
27.
Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008–14.PubMed
28.
Müller C, Domnanich KA, Umbricht CA, van der Meulen NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018;91:20180074.PubMedPubMedCentralCrossRef
29.
Beyer GJ, Miederer M, Vranjes-Durić S, Comor JJ, Künzi G, Hartley O, et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging. 2004;31:547–54.PubMedCrossRef
30.
Gholami YH, Willowson KP, Forwood NJ, Harvie R, Hardcastle N, Bromley R, et al. Comparison of radiobiological parameters for (90)Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro. EJNMMI Phys. 2018;5:1–19.CrossRef
31.
de Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy-how to deal with recoiling daughters? Pharmaceuticals. 2015;8:321–36.PubMedPubMedCentralCrossRef
32.
Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E. Realizing clinical trials with astatine-211: the chemistry infrastructure. Cancer Biother Radiopharm. 2020;35:425–36.PubMedPubMedCentral
33.
Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4–211At astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted alpha-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569–75.PubMedPubMedCentralCrossRef
34.
Gott M, Yang P, Kortz U, Stephan H, Pietzsch HJ, Mamat CA. (224)Ra-labeled polyoxopalladate as a putative radiopharmaceutical. Chem Commun. 2019;55:7631–4.CrossRef
35.
Czerwińska M, Fracasso G, Pruszyński M, Bilewicz A, Kruszewski M, Majkowska-Pilip A, et al. Design and evaluation of (223)Ra-labeled and anti-PSMA targeted NaA nanozeolites for prostate cancer therapy-Part I. Materials. 2020;13:3875.PubMedCentralCrossRef
36.
Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, et al. Preparation of Th227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm. 2007;22:431–7.PubMed
37.
Roscher M, Bakos G, Benešová M. Atomic nanogenerators in targeted alpha therapies: Curie’s legacy in modern cancer management. Pharmaceuticals. 2020;13:76.PubMedCentralCrossRef
38.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.PubMedCrossRef
39.
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–40.PubMedCrossRef
40.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of a-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.PubMedCrossRef
41.
McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–100.PubMed
42.
Filippi L, Chiaravalloti A, Schillaci O, Bagni O. The potential of PSMA-targeted alpha therapy in the management of prostate cancer. Expert Rev Anticancer Ther. 2020;20:823–9.PubMedCrossRef
43.
Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100.PubMedPubMedCentralCrossRef
44.
Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45:31–7.PubMedCrossRef
45.
Pommé S, Marouli M, Suliman G, Dikmen H, Van Ammel R, Jobbágy V, et al. Measurement of the 225Ac half-life. Appl Radiat Isot. 2012;70:2608–14.PubMedCrossRef
46.
Suliman G, Pommé S, Marouli M, Van Ammel R, Stroh H, Jobbágy V, et al. Half-lives of (221)Fr, (217)At, (213)Bi, (213)Po and (209)Pb from the (225)Ac decay series. Appl Radiat Isot. 2013;77:32–7.PubMedCrossRef
47.
Gosewisch A, Schleske M, Gildehaus FJ, Berg I, Kaiser L, Brosch J, et al. Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT. Eur J Nucl Med Mol Imaging. 2021;48:1260–1.PubMedCrossRef
48.
Vatsa R, Sood A, Vadi SK, Das CK, Kaur K, Parmar M, et al. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med. 2020;45:437–8.PubMedCrossRef
49.
Usmani S, Rasheed R, Marafi F, Naqvi SAR. Ac prostate-specific membrane antigen posttherapy α imaging: comparing 2 and 3 photopeaks. Clin Nucl Med. 2019;44:401–3.PubMedCrossRef
50.
Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016;55:123–8.PubMedCrossRef
51.
Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med. 2017;58:1196–200.PubMedCrossRef
52.
53.
Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al. The Iranian society of nuclear medicine practice guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iran J Nucl Med. 2018;26:2–8.
54.
Vorster M, Warwick J, Lawal IO, Du Toit P, Vangu M, Nyakale NE, et al. South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer. S Afr J Surg. 2019;57:45–51.PubMedCrossRef
55.
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.PubMedCrossRef
56.
Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res. 2020;26:2946–55.PubMedPubMedCentralCrossRef
57.
Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, et al. Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med. 2018;59:1076–80.PubMedCrossRef
58.
Lawal I, Vorster M, Boshomane T, Ololade K, Ebenhan T, Sathekge M. Metastatic prostate carcinoma presenting as a superscan on 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:755–6.PubMedCrossRef
59.
Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: α, β, or both? J Nucl Med. 2017;58:1017–8.PubMedCrossRef
60.
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.PubMedCrossRef
61.
Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate. 2017;77:1205–12.PubMedCrossRef
62.
Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. Semin Nucl Med. 2020;50:133–40.PubMedCrossRef
63.
Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759–64.PubMedCrossRef
64.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.PubMedPubMedCentralCrossRef
65.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.PubMedCrossRef
66.
Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D, et al. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1054–62.PubMedCrossRef
67.
Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063–72.
68.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, et al. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate. 2020;80:74–82.
69.
Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469–76.PubMedCrossRef
70.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.CrossRef
71.
Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer. 2018;16:392–401.CrossRef
72.
Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17:15–22.PubMedCrossRef
73.
Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, et al. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. Eur J Nucl Med Mol Imaging. 2021;48:134–42.PubMedCrossRef
74.
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.PubMedCrossRef
75.
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.PubMedCrossRef
76.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62–9.PubMedCrossRef
77.
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020;10:9364–77.PubMedPubMedCentralCrossRef
78.
Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS, et al. Health-related quality-of-life outcomes with Actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med. 2020;35:299–304.PubMedPubMedCentralCrossRef
79.
van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2020;S1078–1439(20)30631–1. https://​doi.​org/​10.​1016/​j.​urolonc.​2020.​12.​002.
80.
Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T, et al. Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617. Eur J Nucl Med Mol Imaging. 2019;46:1756–7.PubMedCrossRef
81.
Maserumule LC, Mokoala KMG, Hlongwa KN, Ndlovu H, Reed JD, Ismail A, et al. Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: a case report. Curr Problems Cancer Case Rep. 2021;3:100038.CrossRef
82.
Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C, et al. First patient exceeding 5-year complete remission after Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging. 2021;48:311–2.PubMedCrossRef
83.
de Medeiros RB, Grigolon MV, Araújo TP, Srougi M. Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report Braj J Oncol. 2019;15:1–9.
84.
Pelletier K, Côté G, Fallah-Rad N, John R, Kitchlu A. CKD after 225Ac-PSMA617 therapy in patients with metastatic prostate cancer. Kidney Int Rep. 2021;6:853–6.PubMedCrossRef
85.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.PubMedCrossRef
86.
Ilhan H, Gosewisch A, Böning G, Völter F, Zacherl M, Unterrainer M, et al. Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:1262–3.
87.
Zacherl MJ, Gildehaus FJ, Mittlmeier L, Böning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62:669–74.
88.
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343–50.PubMedCrossRef
89.
Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8.PubMedCrossRef
90.
Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, et al. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050–60.PubMedPubMedCentralCrossRef
91.
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–62.PubMedCrossRef
92.
Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38.PubMedCrossRef
93.
Kilnoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–36.CrossRef
94.
Lawal IO, Bruchertseifer F, Vorster M, Morgenstern A, Sathekge MM. Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. Curr Opin Urol. 2020;30:98–105.PubMedCrossRef
95.
96.
Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, Muehlematter UJ, et al. First clinicopathologic evidence of a non-PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. J Nucl Med. 2019;60:1270–6.PubMedCrossRef
97.
Yilmaz B, Nisli S, Ergul N, Gursu RU, Acikgoz O, Çermik TF. Effect of external cooling on 177Lu-PSMA uptake by the parotid glands. J Nucl Med. 2019;60:1388–93.PubMedCrossRef
98.
van Kalmthout LWM, Lam MGEH, de Keizer B, Krijger GC, Ververs TFT, de Roos R, et al. Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. EJNMMI Res. 2018;8:56.PubMedPubMedCentralCrossRef
99.
100.
Rousseau E, Lau J, Kuo HT, Zhang Z, Merkens H, Hundal-Jabal N, et al. Monosodium glutamate reduces 68Ga-PSMA-11 uptake in salivary glands and kidneys in a preclinical prostate cancer model. J Nucl Med. 2018;59:1865–8.PubMedPubMedCentralCrossRef
101.
Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano RM, et al. The impact of monosodium glutamate on 68Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study. J Nucl Med. 2021 Jan 28:jnumed.120.257931. https://​doi.​org/​10.​2967/​jnumed.​120.​257931.
102.
Harsini S, Saprunoff H, Alden T, Mohammadi B, Wilson D, Bénard F. The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intraindividual imaging study. J Nucl Med. 2021;62:81–7.PubMedCrossRef
103.
Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli ML, Monti M, et al. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:3008–17.PubMedCrossRef
104.
Felber VB, Valentin MA, Wester HJ. Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? EJNMMI Radiopharm Chem. 2021;6:10.PubMedPubMedCentralCrossRef
105.
Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, et al. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging. 2018;52:80–1.PubMedPubMedCentralCrossRef
106.
Mohan V, Bruin NM, Tesselaar MET, de Boer JP, Vegt E, Hendrikx JJMA, et al. Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine. EJNMMI Res. 2021;11:25.PubMedPubMedCentralCrossRef
107.
Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46:139–47.PubMedCrossRef
108.
Gaertner FC, Halabi K, Ahmadzadehfar H, Kürpig S, Eppard E, Kotsikopoulos C, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8:55094–103.PubMedPubMedCentralCrossRef
109.
Tranel J, Feng FY, James SS, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Phys Med Biol. 2021;66:035016.PubMedCrossRef
110.
111.
Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61:683–8.PubMedCrossRef
112.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.PubMedCrossRef
113.
114.
Kgatle MM, Boshomane TMG, Lawal IO, Mokoala KMG, Mokgoro NP, Lourens N, et al. Immune checkpoints, inhibitor and radionuclides in prostate cancer: promising combinatorial therapy approach. Int J Mol Sci. 2021;22:4109.PubMedPubMedCentralCrossRef
115.
Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, et al. Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med. 2021;62:228–31.PubMedCrossRef
116.
Metadata
Title
Global experience with PSMA-based alpha therapy in prostate cancer
Authors
Mike M. Sathekge
Frank Bruchertseifer
Mariza Vorster
Alfred Morgenstern
Ismaheel O. Lawal
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-021-05434-9

Other articles of this Issue 1/2021

European Journal of Nuclear Medicine and Molecular Imaging 1/2021 Go to the issue

Original Article

Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity

Original Article

Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971

Image of the Month

Increased [68 Ga]Ga-FAPI uptake in focal nodular hyperplasia in a patient with sigmoid colon cancer

Short Communication

[18F]FDG PET/CT imaging disproves renal allograft acute rejection in kidney transplant recipients with acute kidney dysfunction: a validation cohort

Short Communication

High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics

Original Article

Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier